FDA Speeds Drug Checks with Pandemic-Inspired Alternative Tools Guidance
Published Date: 9/12/2025
Notice
Summary
The FDA just released new guidance to help drug makers and applicants understand how the agency will use alternative tools to check drug manufacturing facilities listed in their applications. This change speeds up reviews by using smart methods learned during the COVID-19 pandemic, affecting anyone submitting new drug or biologic applications. These updates start now and aim to make the process smoother without extra costs.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Uses Alternative Tools for Facility Checks
The FDA issued final guidance on how it will use alternative tools to assess drug manufacturing facilities named in marketing applications like NDAs, ANDAs, and BLAs (and supplements). The guidance finalizes the draft issued on September 22, 2023, implements best practices from tools used during the COVID-19 pandemic, and is now available to applicants. The document is tied to PDUFA VII and BsUFA III (Fiscal Years 2023 through 2027) and aims to make the review process smoother without extra costs.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in